{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Placebo&page=25",
    "query": {
      "intervention": "Placebo",
      "page": 25
    },
    "page_size": 10
  },
  "pagination": {
    "page": 25,
    "page_size": 10,
    "total_count": 33137,
    "total_pages": 3314,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Placebo&page=26&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Placebo&page=24&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-11-03T15:50:17.186Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT00030966",
      "title": "Safety and Efficacy of Natalizumab in Combination With Avonex in the Treatment of Multiple Sclerosis",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Multiple Sclerosis, Relapsing-Remitting"
      ],
      "interventions": [
        {
          "name": "Natalizumab",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Biogen",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "55 Years",
        "sex": "ALL",
        "summary": "18 Years to 55 Years"
      },
      "enrollment_count": 1200,
      "start_date": "2002-01",
      "completion_date": "2005-12",
      "has_results": false,
      "last_update_posted_date": "2009-06-18",
      "last_synced_at": "2026-11-03T15:50:17.186Z",
      "location_count": 72,
      "location_summary": "Birmingham, Alabama • Phoenix, Arizona • Little Rock, Arkansas + 59 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Little Rock",
          "state": "Arkansas"
        },
        {
          "city": "Irvine",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00030966"
    },
    {
      "nct_id": "NCT03727022",
      "title": "Safety and Bone Health Study of SM04690 for the Treatment of Moderately to Severely Symptomatic Knee Osteoarthritis",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Knee Osteoarthritis"
      ],
      "interventions": [
        {
          "name": "Placebo",
          "type": "DRUG"
        },
        {
          "name": "SM04690",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Biosplice Therapeutics, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "40 Years",
        "maximum_age": "80 Years",
        "sex": "ALL",
        "summary": "40 Years to 80 Years"
      },
      "enrollment_count": 101,
      "start_date": "2018-11-28",
      "completion_date": "2021-08-18",
      "has_results": true,
      "last_update_posted_date": "2026-01-12",
      "last_synced_at": "2026-11-03T15:50:17.186Z",
      "location_count": 13,
      "location_summary": "Phoenix, Arizona • Canoga Park, California • Carmichael, California + 9 more",
      "locations": [
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Canoga Park",
          "state": "California"
        },
        {
          "city": "Carmichael",
          "state": "California"
        },
        {
          "city": "La Mesa",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03727022"
    },
    {
      "nct_id": "NCT00533429",
      "title": "Study of Pemetrexed + Carboplatin + Bevacizumab + Enzastaurin Versus Pemetrexed + Carboplatin + Bevacizumab + Placebo in Participants With Non-Small Cell Lung Cancer Who Have Not Been Previously Treated With Chemotherapy",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Non-small Cell Lung Cancer"
      ],
      "interventions": [
        {
          "name": "enzastaurin",
          "type": "DRUG"
        },
        {
          "name": "pemetrexed",
          "type": "DRUG"
        },
        {
          "name": "carboplatin",
          "type": "DRUG"
        },
        {
          "name": "bevacizumab",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Eli Lilly and Company",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 40,
      "start_date": "2007-10",
      "completion_date": "2009-02",
      "has_results": true,
      "last_update_posted_date": "2021-05-13",
      "last_synced_at": "2026-11-03T15:50:17.186Z",
      "location_count": 12,
      "location_summary": "Bentonville, Arkansas • Chicago, Illinois • Galesburg, Illinois + 9 more",
      "locations": [
        {
          "city": "Bentonville",
          "state": "Arkansas"
        },
        {
          "city": "Chicago",
          "state": "Illinois"
        },
        {
          "city": "Galesburg",
          "state": "Illinois"
        },
        {
          "city": "Bloomington",
          "state": "Indiana"
        },
        {
          "city": "Evansville",
          "state": "Indiana"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00533429"
    },
    {
      "nct_id": "NCT00782353",
      "title": "Safety, Tolerability, and Antiviral Activity of ANA598 in Patients With Genotype-1 Chronic HCV Infection",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Chronic Hepatitis C"
      ],
      "interventions": [
        {
          "name": "ANA598 200 mg bid or placebo",
          "type": "DRUG"
        },
        {
          "name": "ANA598 400 mg bid or placebo",
          "type": "DRUG"
        },
        {
          "name": "ANA598 800 mg bid or placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Hoffmann-La Roche",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "18 Years to 65 Years"
      },
      "enrollment_count": 35,
      "start_date": "2008-10",
      "completion_date": "2009-03",
      "has_results": false,
      "last_update_posted_date": "2012-11-14",
      "last_synced_at": "2026-11-03T15:50:17.186Z",
      "location_count": 3,
      "location_summary": "St Louis, Missouri • New York, New York • San Antonio, Texas",
      "locations": [
        {
          "city": "St Louis",
          "state": "Missouri"
        },
        {
          "city": "New York",
          "state": "New York"
        },
        {
          "city": "San Antonio",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00782353"
    },
    {
      "nct_id": "NCT03617445",
      "title": "Fecal Microbiota Transplantation for C. Difficile Infection in Solid Organ Transplant Recipients",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Clostridium Difficile Infection Recurrence"
      ],
      "interventions": [
        {
          "name": "FMT oral capsule",
          "type": "DRUG"
        },
        {
          "name": "Oral Vancomycin",
          "type": "DRUG"
        },
        {
          "name": "FMT oral placebo",
          "type": "DRUG"
        },
        {
          "name": "Oral Vancomycin placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "University of Wisconsin, Madison",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 3,
      "start_date": "2022-08-03",
      "completion_date": "2023-06-01",
      "has_results": true,
      "last_update_posted_date": "2025-01-09",
      "last_synced_at": "2026-11-03T15:50:17.186Z",
      "location_count": 5,
      "location_summary": "Chicago, Illinois • Indianapolis, Indiana • Rochester, Minnesota + 2 more",
      "locations": [
        {
          "city": "Chicago",
          "state": "Illinois"
        },
        {
          "city": "Indianapolis",
          "state": "Indiana"
        },
        {
          "city": "Rochester",
          "state": "Minnesota"
        },
        {
          "city": "Columbus",
          "state": "Ohio"
        },
        {
          "city": "Madison",
          "state": "Wisconsin"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03617445"
    },
    {
      "nct_id": "NCT01748877",
      "title": "Efficacy, Tolerability, and Safety of NXN-462 in Patients With Post-Herpetic Neuralgia",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Post Herpetic Neuralgia"
      ],
      "interventions": [
        {
          "name": "NXN-462",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "NeurAxon Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 188,
      "start_date": "2013-01",
      "completion_date": "2014-06",
      "has_results": false,
      "last_update_posted_date": "2014-06-19",
      "last_synced_at": "2026-11-03T15:50:17.186Z",
      "location_count": 22,
      "location_summary": "Phoenix, Arizona • Los Angeles, California • Sacramento, California + 19 more",
      "locations": [
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Sacramento",
          "state": "California"
        },
        {
          "city": "Santa Monica",
          "state": "California"
        },
        {
          "city": "Brooksville",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01748877"
    },
    {
      "nct_id": "NCT01190475",
      "title": "BGS649 Monotherapy in Moderate to Severe Endometriosis Patients",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Endometriosis"
      ],
      "interventions": [
        {
          "name": "Active treatment with a high dose of BGS649",
          "type": "DRUG"
        },
        {
          "name": "Active treatment with a low dose of BGS649",
          "type": "DRUG"
        },
        {
          "name": "Placebo treatment to blind study",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Mereo BioPharma",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "40 Years",
        "sex": "FEMALE",
        "summary": "18 Years to 40 Years · Female only"
      },
      "enrollment_count": 6,
      "start_date": "2010-07",
      "completion_date": "2011-09",
      "has_results": true,
      "last_update_posted_date": "2020-10-27",
      "last_synced_at": "2026-11-03T15:50:17.186Z",
      "location_count": 1,
      "location_summary": "Anaheim, California",
      "locations": [
        {
          "city": "Anaheim",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01190475"
    },
    {
      "nct_id": "NCT03745781",
      "title": "Open-Label Placebo for Functional Dyspepsia",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "EARLY_PHASE1"
      ],
      "conditions": [
        "Dyspepsia"
      ],
      "interventions": [
        {
          "name": "Placebos",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Beth Israel Deaconess Medical Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "80 Years",
        "sex": "ALL",
        "summary": "18 Years to 80 Years"
      },
      "enrollment_count": 21,
      "start_date": "2018-12-01",
      "completion_date": "2019-10-07",
      "has_results": false,
      "last_update_posted_date": "2020-05-06",
      "last_synced_at": "2026-11-03T15:50:17.186Z",
      "location_count": 1,
      "location_summary": "Boston, Massachusetts",
      "locations": [
        {
          "city": "Boston",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03745781"
    },
    {
      "nct_id": "NCT01449630",
      "title": "A Study of LY3031207 in Healthy Subjects",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Healthy Volunteers"
      ],
      "interventions": [
        {
          "name": "LY3031207",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        },
        {
          "name": "Celecoxib",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Eli Lilly and Company",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "60 Years",
        "sex": "ALL",
        "summary": "18 Years to 60 Years"
      },
      "enrollment_count": 29,
      "start_date": "2011-10-24",
      "completion_date": "2012-04-02",
      "has_results": true,
      "last_update_posted_date": "2019-07-05",
      "last_synced_at": "2026-11-03T15:50:17.186Z",
      "location_count": 1,
      "location_summary": "Evansville, Indiana",
      "locations": [
        {
          "city": "Evansville",
          "state": "Indiana"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01449630"
    },
    {
      "nct_id": "NCT01329965",
      "title": "Safety and Feasibility of an Endotoxemia Model",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Cardiovascular Disease",
        "Inflammation"
      ],
      "interventions": [
        {
          "name": "LPS (reference endotoxin, E. coli O113:H10:K:neg, manufactured under GMP)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Penn State University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "20 Years",
        "maximum_age": "35 Years",
        "sex": "ALL",
        "summary": "20 Years to 35 Years"
      },
      "enrollment_count": 6,
      "start_date": "2011-04",
      "completion_date": "2011-09",
      "has_results": false,
      "last_update_posted_date": "2023-08-21",
      "last_synced_at": "2026-11-03T15:50:17.186Z",
      "location_count": 1,
      "location_summary": "University Park, Pennsylvania",
      "locations": [
        {
          "city": "University Park",
          "state": "Pennsylvania"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01329965"
    }
  ]
}